A closer look at pain and hepatitis C: Preliminary data from a veteran population

Silberbogen, Amy K.; Janke, E. Amy; Hebenstreit, Claire L.

doi:10.1682/jrrd.2006.05.0053

Cited by 34 publications

(40 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15,16 Heterogeneous clinical conditions account for the sites of pain-low back, legs, total body-that comprise the majority of pain complaints among opioid-dependent patients. 6,17 Pain in this population has been attributed to past traumatic injuries, chronic medical conditions, human immunodeficiency virus and hepatitis C virus infection, 18,19 opioid-induced hyperalgesia, 20 and non-specific factors unrelated to opioid withdrawal. 17 While buprenorphine has analgesic properties, it is not typically initiated, dosed, or directed toward pain relief in opioid-dependent persons.…”

Section: Introductionmentioning

confidence: 99%

Chronic Pain and DepressionAmong Primary Care Patients Treated with Buprenorphine

et al. 2015

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Chronic Pain and DepressionAmong Primary Care Patients Treated with Buprenorphine

et al. 2015

View full text Add to dashboard Cite

“…La revisión de Lovy (16) se basa en el síndrome denominado Cryoglobulinemia esencial; según este autor, cuando se desencadenan crioprecipitados específicos que contienen inmunoglobulinas policlonales de tipo II, que secretan Inmunoglobulina G y M que a su vez actúan a nivel hepático, se favorece la aparición de FM. La segunda revisión (17) propone que la infección viral y la subsiguiente inflamación producida por la hepatitis C puede iniciar una cadena de eventos bioquímicos que llevan a la aparición de FM. En un estudio de cohortes realizado por Buskila (18), se siguió dos años consecutivos a 90 pacientes diagnosticados de hepatitis C, no tratados con interferón; de ellos, 22 (14 %) cumplieron con los criterios diagnósticos del ACR para FM y se encontró una incidencia mas alta de enfermedades reumáticas (p<0.5).…”

Section: Resultsunclassified

¿Qué sabemos sobre los Factores de Riesgo de la Fibromialgia?: what do we know about risk factors?

Medrano¹,

Ronda-Pérez²,

Vives‐Cases³

et al. 2009

Rev. salud pública

View full text Add to dashboard Cite

RESUMENObjetivo El objetivo de este trabajo es describir las principales características de los artículos publicados en revistas científicas entre los años 1992 y 2007 que aborden el análisis de los factores etiológicos asociados a esta patología. Material y Método Revisión sistemática de artículos científicos sobre esta asociación, utilizando las bases de datos de ciencias de la salud y sociales: Medline, Cinhal, Web of Science, Lilacs, Sociological Abstracts, Cuiden, Embase, PsycoInfo e ISI Web of Knowledge. Resultados Se ha obtenido en el período de estudio 21 artículos, distribuidos así: 7 (33,3 %) revisiones teóricas, 6 (28,5 %) estudios transversales, 4 (19,0 %) estudios de cohortes, 2 (9,5 %) estudios de casos y controles y 1 (4,7 %) revisión sistemática. De éstos, 7 (33,3 %) consideraban como factor de riesgo el estrés, 3 (14,3 %) la hepatitis C, 4 (19,0 %) antecedente traumático, 3 (14,3 %) la ocupación y en 4 (19,0 %) se asoció la aparición a otros factores como los implantes de silicona, el tabaco, los factores sociodemográficos y factores hormonales. El período temporal más productivo fue 2000-2004. Se observa una gran dispersión temática en las revistas de publicación. Discusión La evidencia empírica existente en torno a los factores de riesgo de la fibromialgia es todavía escasa y dispersa. Estudios futuros deberían centrarse en generar más conocimiento sobre los factores de riesgo estudiados, para así poder contribuir a mejorar la atención, diagnóstico y tratamiento de la fibromialgia.Palabras Clave: Fibromialgia, etiología, factores de riesgo (fuente: DeCS, BIREME). ABSTRACTObjective This study was aimed at describing the main features of articles published in scientific journals between 1992 and 2007 addressing the analysis of the etiological factors associated with this condition. Materials and Methods This consisted of a systematic review of scientific articles regarding this association using the following health and social science databases: Medline, 662

show abstract

“…Given that the literature describes opioid-using populations to be at increased risk of hepatitis B, 21 hepatitis C, 21,22 HIV, 23 depression, [24][25][26] and anxiety, 27 data regarding these conditions were obtained from birth certificate data and from outpatient and hospital administrative records by using diagnostic codes (hepatitis B: 070.2x and 070.3x; hepatitis C: 070. 41 …”

Section: Maternal Characteristicsmentioning

confidence: 99%

Prescription Opioid Epidemic and Infant Outcomes

2015

PEDIATRICS

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: Although opioid pain relievers are commonly prescribed in pregnancy, their association with neonatal outcomes is poorly described. Our objectives were to identify neonatal complications associated with antenatal opioid pain reliever exposure and to establish predictors of neonatal abstinence syndrome (NAS). METHODS:We used prescription and administrative data linked to vital statistics for mothers and infants enrolled in the Tennessee Medicaid program between 2009 and 2011. A random sample of NAS cases was validated by medical record review. The association of antenatal exposures with NAS was evaluated by using multivariable logistic regression, controlling for maternal and infant characteristics.RESULTS: Of 112 029 pregnant women, 31 354 (28%) filled $1 opioid prescription. Women prescribed opioid pain relievers were more likely than those not prescribed opioids (P , .001) to have depression (5.3% vs 2.7%), anxiety disorder (4.3% vs 1.6%) and to smoke tobacco (41.8% vs 25.8%). Infants with NAS and opioid-exposed infants were more likely than unexposed infants to be born at a low birth weight (21.2% vs 11.8% vs 9.9%; P , .001). In a multivariable model, higher cumulative opioid exposure for short-acting preparations (P , .001), opioid type (P , .001), number of daily cigarettes smoked (P , .001), and selective serotonin reuptake inhibitor use (odds ratio: 2.08 [95% confidence interval: 1.67-2.60]) were associated with greater risk of developing NAS.CONCLUSIONS: Prescription opioid use in pregnancy is common and strongly associated with neonatal complications. Antenatal cumulative prescription opioid exposure, opioid type, tobacco use, and selective serotonin reuptake inhibitor use increase the risk of NAS. WHAT'S KNOWN ON THIS SUBJECT:Although opioid pain relievers are commonly prescribed in pregnancy, their association with neonatal outcomes is not well described. Further, factors associated with development of neonatal abstinence syndrome, a neonatal opioid withdrawal syndrome is inadequately understood.WHAT THIS STUDY ADDS: Prescription opioid use in pregnancy is common and strongly associated with neonatal complications. Antenatal cumulative prescription opioid exposure, opioid type, tobacco use, and selective serotonin reuptake inhibitor use increase the risk of neonatal abstinence syndrome.

show abstract

A closer look at pain and hepatitis C: Preliminary data from a veteran population

Cited by 34 publications

References 77 publications

Chronic Pain and DepressionAmong Primary Care Patients Treated with Buprenorphine

Chronic Pain and DepressionAmong Primary Care Patients Treated with Buprenorphine

¿Qué sabemos sobre los Factores de Riesgo de la Fibromialgia?: what do we know about risk factors?

Prescription Opioid Epidemic and Infant Outcomes

Contact Info

Product

Resources

About